Home / Health / Children to Trial Novo Nordisk's Next-Gen Weight Drug
Children to Trial Novo Nordisk's Next-Gen Weight Drug
2 Dec
Summary
- Novo Nordisk will test its experimental obesity drug CagriSema in children.
- The late-stage trial starts in January with 460 participants.
- CagriSema combines two hormones to mimic pancreatic function.
Novo Nordisk is preparing to initiate a significant clinical trial for its experimental obesity medication, CagriSema, in pediatric patients. This drug, a combination of cagrilintide and semaglutide, aims to offer a more potent solution for weight management.
The upcoming late-stage trial is scheduled to begin in January and will enroll approximately 460 children aged eight and older. These trials will span 97 test centers globally, including locations in the United States, China, and Europe, to gather comprehensive data on the drug's efficacy and safety.
Participants will be randomly assigned to receive either CagriSema, cagrilintide alone, semaglutide alone, or a placebo. The primary outcome measure will be the change in body weight from baseline after 68 weeks of treatment. This development follows earlier studies where CagriSema yielded lower-than-anticipated weight loss results, prompting Novo Nordisk to launch this new, extensive trial.
